文献速递前列腺癌

YAP1在高分级前列腺腺癌中表达升高但在神经内分泌前列腺癌中表达降低

The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-04-20

该研究通过免疫组化和生物信息学分析评估YAP1在前列腺癌发生和进展中的表达。结果显示YAP1在良性前列腺基底上皮细胞中表达,低级别前列腺癌中丢失,高级别前列腺腺癌中升高,而在人类和小鼠神经内分泌前列腺癌(NEPC)中表达降低或丢失。

要点

  • YAP1在良性前列腺基底上皮细胞中表达,在低级别前列腺癌中丢失。
  • YAP1在高级别前列腺腺癌中表达升高。
  • YAP1在人类和小鼠神经内分泌前列腺癌中表达降低或丢失。

核心结论

  • YAP1在前列腺腺癌高级别中表达升高,但在神经内分泌前列腺癌中表达丢失。

研究设计与样本

  • 采用免疫组织化学和生物信息学分析评估YAP1在前列腺癌发生和进展中的表达水平。

主要发现

  • YAP1表达存在于良性前列腺组织的基底上皮细胞中。
  • YAP1在低级别前列腺癌中丢失,但在高级别前列腺腺癌中升高。
  • YAP1在人类和小鼠神经内分泌前列腺癌中表达降低或丢失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After long-term androgen deprivation therapy, 25-30% prostate cancer (PCa) acquires an aggressive neuroendocrine (NE) phenotype. Dysregulation of YAP1, a key transcription coactivator of the Hippo pathway, has been related to cancer progression. However, its role in neuroendocrine prostate cancer (NEPC) has not been assessed. METHODS: Immunohistochemistry and bioinformatics analysis were conducted to evaluate YAP1 expression levels during PCa initiation and progression. RESULTS: YAP1 expression was present in the basal epithelial cells in benign prostatic tissues, lost in low-grade PCa, but elevated in high-grade prostate adenocarcinomas. Interestingly, the expression of YAP1 was reduced/lost in both human and mouse NEPC. CONCLUSIONS: The expression of YAP1 is elevated in high-grade prostate adenocarcinomas but lost in NEPC.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Cheng S, Prieto-Dominguez N, Yang S, et al. The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer. Prostate Cancer Prostatic Dis. 2020. PMID: 32313141. doi:10.1038/s41391-020-0229-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。